### Recommended Immunization Schedule for Persons Aged 0-6 Years—UNITED STATES • 2007

Vaccine ▼ Age ►	Birth	1 month	2 months	4 months	6 months	12 months	15 months	18 months	19–23 months	2–3 years	4–6 years
Hepatitis B¹	НерВ	НерВ		see footnote 1	НерВ				HepB Series		
Rotavirus <sup>2</sup>			Rota	Rota	Rota						
Diphtheria, Tetanus, Pertussis³		-	DTaP	DTaP	DTaP	DTaP				DTaP	
Haemophilus influenzae type b⁴			Hib	Hib	Hib⁴	Hib		Ніь			
Pneumococcal⁵			PCV	PCV	PCV	PCV				PCV PPV	
Inactivated Poliovirus			IPV	IPV		IF	v				IPV
Influenza <sup>6</sup>					Influenza (Yearly)						
Measles, Mumps, Rubella <sup>7</sup>						MI	VIR				MMR
Varicella <sup>8</sup>						Vari	cella				Varicella
Hepatitis A <sup>9</sup>							HepA (	2 doses		НерА	Series
Meningococcal <sup>10</sup>										MP	SV4

Range of recommended ages

Catch-up immunization

Certain high-risk groups

This schedule indicates the recommended ages for routine administration of currently licensed childhood vaccines, as of December 1, 2006, for children aged 0–6 years. Additional information is available at <a href="http://www.cdc.gov/nip/recs/child-schedule.htm">http://www.cdc.gov/nip/recs/child-schedule.htm</a>. Any dose not administered at the recommended age should be administered at any subsequent visit, when indicated and feasible. Additional vaccines may be licensed and recommended during the year. Licensed combination vaccines may be used whenever any components of the combination are indicated and

other components of the vaccine are not contraindicated and if approved by the Food and Drug Administration for that dose of the series. Providers should consult the respective Advisory Committee on Immunization Practices statement for detailed recommendations. Clinically significant adverse events that follow immunization should be reported to the Vaccine Adverse Event Reporting System (VAERS). Guidance about how to obtain and complete a VAERS form is available at <a href="http://www.vaers">http://www.vaers</a>, <a href="https://www.vaers">https://www.vaers</a>, <a href="https://www.vaers">https://www.vaers</a

# 1. Hepatitis B vaccine (HepB). (Minimum age: birth) At birth:

- Administer monovalent HepB to all newborns before hospital discharge.
- If mother is hepatitis surface antigen (HBsAg)-positive, administer HepB and 0.5 mL of hepatitis B immune globulin (HBIG) within 12 hours of birth.
- If mother's HBsAg status is unknown, administer HepB within 12 hours of birth. Determine the HBsAg status as soon as possible and if HBsAg-positive, administer HBIG (no later than age 1 week).
- If mother is HBsAg-negative, the birth dose can only be delayed with physician's order and mother's negative HBsAg laboratory report documented in the infant's medical record.

#### After the birth dose:

• The HepB series should be completed with either monovalent HepB or a combination vaccine containing HepB. The second dose should be administered at age 1–2 months. The final dose should be administered at age ≥24 weeks. Infants born to HBsAg-positive mothers should be tested for HBsAg and antibody to HBsAg after completion of ≥3 doses of a licensed HepB series, at age 9–18 months (generally at the next well-child visit).

#### 4-month dose:

- It is permissible to administer 4 doses of HepB when combination vaccines are administered after the birth dose. If monovalent HepB is used for doses after the birth dose, a dose at age 4 months is not needed.
- 2. Rotavirus vaccine (Rota). (Minimum age: 6 weeks)
  - Administer the first dose at age 6–12 weeks. Do not start the series later than age 12 weeks.
  - Administer the final dose in the series by age 32 weeks. Do not administer a dose later than age 32 weeks.
  - · Data on safety and efficacy outside of these age ranges are insufficient.
- 3. Diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP). (Minimum age: 6 weeks)
  - The fourth dose of DTaP may be administered as early as age 12 months, provided 6 months have elapsed since the third dose.
  - Administer the final dose in the series at age 4-6 years.
- 4. Haemophilus influenzae type b conjugate vaccine (Hib). (Minimum age: 6 weeks)
  - If PRP-OMP (PedvaxHIB® or ComVax® [Merck]) is administered at ages 2 and 4 months, a dose at age 6 months is not required.
  - TriHiBit<sup>®</sup> (DTaP/Hib) combination products should not be used for primary immunization but can be used as boosters following any Hib vaccine in children aged ≥12 months.

- Pneumococcal vaccine. (Minimum age: 6 weeks for pneumococcal conjugate vaccine (PCVI); 2 years for pneumococcal polysaccharide vaccine (PPVI)
  - Administer PCV at ages 24–59 months in certain high-risk groups.
     Administer PPV to children aged ≥2 years in certain high-risk groups.
     See MMWR 2000;49(No. RR-9):1–35.
- 6. Influenza vaccine. (Minimum age: 6 months for trivalent inactivated influenza vaccine [TIV]; 5 years for live, attenuated influenza vaccine [LAIV])
  - All children aged 6–59 months and close contacts of all children aged 0–59 months are recommended to receive influenza vaccine.
  - Influenza vaccine is recommended annually for children aged ≥59 months with certain risk factors, health-care workers, and other persons (including household members) in close contact with persons in groups at high risk. See MMWR 2006;55(No. RR-10):1–41.
  - For healthy persons aged 5–49 years, LAIV may be used as an alternative to TIV.
  - Children receiving TIV should receive 0.25 mL if aged 6–35 months or 0.5 mL if aged ≥3 years.
  - Children aged <9 years who are receiving influenza vaccine for the first time should receive 2 doses (separated by ≥4 weeks for TIV and ≥6 weeks for LAIV).
- 7. Measles, mumps, and rubella vaccine (MMR). (Minimum age: 12 months)
  - Administer the second dose of MMR at age 4–6 years. MMR may be administered before age 4–6 years, provided ≥4 weeks have elapsed since the first dose and both doses are administered at age ≥12 months.
- 8. Varicella vaccine. (Minimum age: 12 months)
  - Administer the second dose of varicella vaccine at age 4–6 years.
     Varicella vaccine may be administered before age 4–6 years, provided that ≥3 months have elapsed since the first dose and both doses are administered at age ≥12 months. If second dose was administered ≥28 days following the first dose, the second dose does not need to be repeated.
- 9. Hepatitis A vaccine (HepA). (Minimum age: 12 months)
  - HepA is recommended for all children aged 1 year (i.e., aged 12–23 months).
     The 2 doses in the series should be administered at least 6 months apart.
  - Children not fully vaccinated by age 2 years can be vaccinated at subsequent visits.
  - HepA is recommended for certain other groups of children, including in areas where vaccination programs target older children. See MMWR 2006;55(No. RR-7):1–23.
- 10. Meningococcal polysaccharide vaccine (MPSV4). (Minimum age: 2 years)
  - Administer MPSV4 to children aged 2–10 years with terminal complement deficiencies or anatomic or functional asplenia and certain other highrisk groups. See MMWR 2005;54(No. RR-7):1–21.

# Recommended Immunization Schedule for Persons Aged 7-18 Years—UNITED STATES • 2007

Vaccine <b>▼</b>	7-10 years	11-12 YEARS	13-14 years	15 years	16-18 years			
Tetanus, Diphtheria, Pertussis¹	see footnote	Tdap		Range of recommend ages				
Human Papillomavirus²	see footnote	HPV (3 doses)						
Meningococcal <sup>3</sup>	MPSV4	MCV4						
Pneumococcal⁴		Catch-up immunizati						
Influenza <sup>5</sup>	Influenza (Yearly)							
Hepatitis A <sup>6</sup>		HepA Series						
Hepatitis B <sup>7</sup>		HepB Series				groups		
Inactivated Poliovirus®		IPV Series						
Measles, Mumps, Rubella <sup>9</sup>		MMR Series						
Varicella <sup>10</sup>		Varicella Series						

This schedule indicates the recommended ages for routine administration of currently licensed childhood vaccines, as of December 1, 2006, for children aged 7–18 years. Additional information is available at <a href="http://www.cdc.gov/nip/recs/child-schedule.htm">http://www.cdc.gov/nip/recs/child-schedule.htm</a>. Any dose not administered at the recommended age should be administered at any subsequent visit, when indicated and feasible. Additional vaccines may be licensed and recommended during the year. Licensed combination vaccines may be used whenever any components of the combination are indicated and other components

of the vaccine are not contraindicated and if approved by the Food and Drug Administration for that dose of the series. Providers should consult the respective Advisory Committee on Immunization Practices statement for detailed recommendations. Clinically significant adverse events that follow immunization should be reported to the Vaccine Adverse Event Reporting System (VAERS). Guidance about how to obtain and complete a VAERS form is available at <a href="http://www.vaers.hhs.gov">http://www.vaers.hhs.gov</a> or by telephone, 800-822-7967.

#### Tetanus and diphtheria toxoids and acellular pertussis vaccine (Tdap).

(Minimum age: 10 years for BOOSTRIX® and 11 years for ADACEL™)

- Administer at age 11–12 years for those who have completed the recommended childhood DTP/DTaP vaccination series and have not received a tetanus and diphtheria toxoids vaccine (Td) booster dose.
- Adolescents aged 13–18 years who missed the 11–12 year Td/Tdap booster dose should also receive a single dose of Tdap if they have completed the recommended childhood DTP/DTaP vaccination series.

#### 2. Human papillomavirus vaccine (HPV). (Minimum age: 9 years)

- Administer the first dose of the HPV vaccine series to females at age 11–12 years.
- Administer the second dose 2 months after the first dose and the third dose
   6 months after the first dose.
- Administer the HPV vaccine series to females at age 13–18 years if not previously vaccinated.
- Meningococcal vaccine. (Minimum age: 11 years for meningococcal conjugate vaccine [MCV4]; 2 years for meningococcal polysaccharide vaccine [MPSV4])
  - Administer MCV4 at age 11–12 years and to previously unvaccinated adolescents at high school entry (at approximately age 15 years).
  - Administer MCV4 to previously unvaccinated college freshmen living in dormitories; MPSV4 is an acceptable alternative.
  - Vaccination against invasive meningococcal disease is recommended for children and adolescents aged ≥2 years with terminal complement deficiencies or anatomic or functional asplenia and certain other high-risk groups. See MMWR 2005;54(No. RR-7):1–21. Use MPSV4 for children aged 2–10 years and MCV4 or MPSV4 for older children.
- 4. Pneumococcal polysaccharide vaccine (PPV). (Minimum age: 2 years)
  - Administer for certain high-risk groups. See MMWR 1997;46(No. RR-8):1–24, and MMWR 2000;49(No. RR-9):1–35.

- Influenza vaccine. (Minimum age: 6 months for trivalent inactivated influenza vaccine [TIV]; 5 years for live, attenuated influenza vaccine [LAIV])
  - Influenza vaccine is recommended annually for persons with certain risk factors, health-care workers, and other persons (including household members) in close contact with persons in groups at high risk. See MMWR 2006;55 (No. RR-10):1–41.
  - For healthy persons aged 5–49 years, LAIV may be used as an alternative to TIV.
  - Children aged <9 years who are receiving influenza vaccine for the first time should receive 2 doses (separated by ≥4 weeks for TIV and ≥6 weeks for LAIV).
- 6. Hepatitis A vaccine (HepA). (Minimum age: 12 months)
  - The 2 doses in the series should be administered at least 6 months apart.
  - HepA is recommended for certain other groups of children, including in areas where vaccination programs target older children. See MMWR 2006;55 (No. RR-7):1–23.
- 7. Hepatitis B vaccine (HepB). (Minimum age: birth)
  - Administer the 3-dose series to those who were not previously vaccinated.
  - A 2-dose series of Recombivax HB® is licensed for children aged 11–15 years.
- 8. Inactivated poliovirus vaccine (IPV). (Minimum age: 6 weeks)
  - For children who received an all-IPV or all-oral poliovirus (OPV) series, a fourth dose is not necessary if the third dose was administered at age ≥4 years.
  - If both OPV and IPV were administered as part of a series, a total of 4 doses should be administered, regardless of the child's current age.
- 9. Measles, mumps, and rubella vaccine (MMR). (Minimum age: 12 months)
  - If not previously vaccinated, administer 2 doses of MMR during any visit, with ≥4 weeks between the doses.
- 10. Varicella vaccine. (Minimum age: 12 months)
  - · Administer 2 doses of varicella vaccine to persons without evidence of immunity.
  - Administer 2 doses of varicella vaccine to persons aged <13 years at least 3 months apart. Do not repeat the second dose, if administered ≥28 days after the first dose.
  - Administer 2 doses of varicella vaccine to persons aged ≥13 years at least 4 weeks apart.

### Recommended Immunization Schedule for Persons Aged 0-6 Years—UNITED STATES • 2007

Vaccine ▼ Age ►	Birth	1 month	2 months	4 months	6 months	12 months	15 months	18 months	19–23 months	2–3 years	4–6 years
Hepatitis B¹	НерВ	НерВ		see footnote 1	HepB				HepB Series		
Rotavirus <sup>2</sup>			Rota	Rota	Rota						
Diphtheria, Tetanus, Pertussis³			DTaP	DTaP	DTaP	DTaP DTaP		ГаР			DTaP
Haemophilus influenzae type b⁴			Hib	Hib	Hib⁴	н	ib		Hib		
Pneumococcal <sup>5</sup>			PCV	PCV	PCV	PCV			PCV PPV		
Inactivated Poliovirus			IPV	IPV		IF	V				IPV
Influenza <sup>6</sup>					Influenza (Yearly)						
Measles, Mumps, Rubella <sup>7</sup>						MI	MR				MMR
Varicella <sup>8</sup>						Vari	cella				Varicella
Hepatitis A <sup>9</sup>							HepA (	2 doses		НерА	Series
Meningococcal <sup>10</sup>										MP	SV4

Range of recommended ages

Catch-up immunization

Certain high-risk groups

This schedule indicates the recommended ages for routine administration of currently licensed childhood vaccines, as of December 1, 2006, for children aged 0–6 years. Additional information is available at http://www.cdc.gov/nip/recs/child-schedule.htm. Any dose not administered at the recommended age should be administered at any subsequent visit, when indicated and feasible. Additional vaccines may be licensed and recommended during the year. Licensed combination vaccines may be used whenever any components of the combination are indicated and

other components of the vaccine are not contraindicated and if approved by the Food and Drug Administration for that dose of the series. Providers should consult the respective Advisory Committee on Immunization Practices statement for detailed recommendations. Clinically significant adverse events that follow immunization should be reported to the Vaccine Adverse Event Reporting System (VAERS). Guidance about how to obtain and complete a VAERS form is available at http://www.vaers, hhs.gov or by telephone, 800-822-7967.

# 1. Hepatitis B vaccine (HepB). (Minimum age: birth) At birth:

- · Administer monovalent HepB to all newborns before hospital discharge.
- If mother is hepatitis surface antigen (HBsAg)-positive, administer HepB and 0.5 mL of hepatitis B immune globulin (HBIG) within 12 hours of birth.
- If mother's HBsAg status is unknown, administer HepB within 12 hours of birth. Determine the HBsAg status as soon as possible and if HBsAg-positive, administer HBIG (no later than age 1 week).
- If mother is HBsAg-negative, the birth dose can only be delayed with physician's order and mother's negative HBsAg laboratory report documented in the infant's medical record.

#### After the birth dose:

• The HepB series should be completed with either monovalent HepB or a combination vaccine containing HepB. The second dose should be administered at age 1–2 months. The final dose should be administered at age ≥24 weeks. Infants born to HBsAg-positive mothers should be tested for HBsAg and antibody to HBsAg after completion of ≥3 doses of a licensed HepB series, at age 9–18 months (generally at the next well-child visit).

#### 4-month dose:

- It is permissible to administer 4 doses of HepB when combination vaccines are administered after the birth dose. If monovalent HepB is used for doses after the birth dose, a dose at age 4 months is not needed.
- 2. Rotavirus vaccine (Rota). (Minimum age: 6 weeks)
  - Administer the first dose at age 6–12 weeks. Do not start the series later than age 12 weeks.
  - Administer the final dose in the series by age 32 weeks. Do not administer a dose later than age 32 weeks.
  - · Data on safety and efficacy outside of these age ranges are insufficient.
- Diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP). (Minimum age: 6 weeks)
  - The fourth dose of DTaP may be administered as early as age 12 months, provided 6 months have elapsed since the third dose.
  - Administer the final dose in the series at age 4–6 years.
- 4. Haemophilus influenzae type b conjugate vaccine (Hib). (Minimum age: 6 weeks)
  - If PRP-OMP (PedvaxHIB® or ComVax® [Merck]) is administered at ages 2 and 4 months, a dose at age 6 months is not required.
  - TriHiBit® (DTaP/Hib) combination products should not be used for primary immunization but can be used as boosters following any Hib vaccine in children aged ≥12 months.

- 5. Pneumococcal vaccine. (Minimum age: 6 weeks for pneumococcal conjugate vaccine (PCVI: 2 years for pneumococcal polysaccharide vaccine (PPV))
  - Administer PCV at ages 24–59 months in certain high-risk groups.
     Administer PPV to children aged ≥2 years in certain high-risk groups.
     See MMWR 2000;49(No. RR-9):1–35.
- 6. Influenza vaccine. (Minimum age: 6 months for trivalent inactivated influenza vaccine [TIV]; 5 years for live, attenuated influenza vaccine [LAIV])
  - All children aged 6–59 months and close contacts of all children aged 0–59 months are recommended to receive influenza vaccine.
  - Influenza vaccine is recommended annually for children aged ≥59 months with certain risk factors, health-care workers, and other persons (including household members) in close contact with persons in groups at high risk. See MMWR 2006;55(No. RR-10):1–41.
  - For healthy persons aged 5–49 years, LAIV may be used as an alternative to TIV.
  - Children receiving TIV should receive 0.25 mL if aged 6–35 months or 0.5 mL if aged ≥3 years.
  - Children aged <9 years who are receiving influenza vaccine for the first time should receive 2 doses (separated by ≥4 weeks for TIV and ≥6 weeks for LAIV).
- 7. Measles, mumps, and rubella vaccine (MMR). (Minimum age: 12 months)
- Administer the second dose of MMR at age 4–6 years. MMR may be administered before age 4–6 years, provided ≥4 weeks have elapsed since the first dose and both doses are administered at age ≥12 months.
- 8. Varicella vaccine. (Minimum age: 12 months)
  - Administer the second dose of varicella vaccine at age 4–6 years.
     Varicella vaccine may be administered before age 4–6 years, provided that ≥3 months have elapsed since the first dose and both doses are administered at age ≥12 months. If second dose was administered ≥28 days following the first dose, the second dose does not need to be repeated.
- 9. Hepatitis A vaccine (HepA). (Minimum age: 12 months)
  - HepA is recommended for all children aged 1 year (i.e., aged 12–23 months).
     The 2 doses in the series should be administered at least 6 months apart.
  - Children not fully vaccinated by age 2 years can be vaccinated at subsequent visits.
  - HepA is recommended for certain other groups of children, including in areas where vaccination programs target older children. See MMWR 2006;55(No. RR-7):1–23.
- 10. Meningococcal polysaccharide vaccine (MPSV4). (Minimum age: 2 years)
- Administer MPSV4 to children aged 2–10 years with terminal complement deficiencies or anatomic or functional asplenia and certain other highrisk groups. See MMWR 2005;54(No. RR-7):1–21.